Список литературы

1. Савельева Г.М., Курцер М.А., Панина О.Б., Сичинава Л.Г., Коноплянников А.Г. Гемолитическая болезнь плода у беременных с резус-сенсибилизацией. Диагностика, лечение, профилактика. Методическое письмо Минздравсоцразвития, 2012. - 18 с.

2. Коноплянников А.Г., Павлова Н.Г. Изосерологическая несовместимость крови матери и плода. Гемолитическая болезнь плода и новорожденных. В кн.: Акушерство. Национальное руководство. 2015: с. 324 - 334.

3. Антонов А.Г., Дегтярев Д.Н., Нароган М.В., Карпова А.Л., Сенькевич О.А., Сафаров А.А., Сон Е.Д., Малютина Л.В. Гемолитическая болезнь новорожденных. В кн.: Неонатология. Клинические рекомендации/под ред. Н.Н. Володин, Д.Н. Дегтярев, Д.С. Крючко. М., ГЭОТАР-Медиа 2019. - С. 19 - 35.

4. Савельева Г.М., Адамян Л.В., Курцер М.А., Сичинава Л.Г., Панина О.Б., Коноплянников А.Г., Тетруашвили Н.К., Михайлов А.В., Филиппов О.С. Резус-сенсибилизация. Гемолитическая болезнь плода. Клинические рекомендации (протокол). М., 2017. 16 с.

5. Неонатология: национальное руководство/под ред. Н.Н. Володина. М.: ГЭОТАР-Медиа, 2007. 848 с.

6. White J., Qureshi H., Massey E., Needs M., Byrne G., Daniels G., Allard S., British Committee for Standards in Haematology. Guideline for blood grouping and red cell antibody testing in pregnancy. Transfus Med. 2016; 26(4): 246-63. doi: 10.1111/tme.12299.

7. McBain R.D., Crowther C.A., Middleton P. Anti-D administration in pregnancy for preventing Rhesus alloimmunisation. Cochrane database Syst Rev. 2015; (9):CD000020. doi: 10.1002/14651858.CD000020.pub3.

8. Guidelines for blood grouping and red cell antibody testing during pregnancy. British Committee for Standards in Haematology, Blood Transfusion Task Force. Transfus Med. 1996; 6(1): 71-4.

9. Weiner C.P. Human fetal bilirubin levels and fetal hemolytic disease. Am J Obstet Gynecol. 1992; 166(5): 1449-54. doi: 10.1016/0002-9378(92)91618-k.

10. Weiner C.P., Williamson R.A., Wenstrom K.D., Sipes S.L., Grant S.S., Widness J.A. Management of fetal hemolytic disease by cordocentesis. I. Prediction of fetal anemia. Am J Obstet Gynecol. 1991; 165(3): 546-53. doi: 10.1016/0002-9378(91)90281-u.

11. Weiner C.P., Widness J.A. Decreased fetal erythropoiesis and hemolysis in Kell hemolytic anemia. Am J Obstet Gynecol. 1996; 174(2): 547-51. doi: 10.1016/s0002-9378(96)70425-8.

12. Oepkes D., Seaward P.G., Vandenbussche F.P.H.A., Windrim R., Kingdom J., Beyene J., Kanhai H.H.H., Ohlsson A., Ryan G., DIAMOND Study Group. Doppler ultrasonography versus amniocentesis to predict fetal anemia. N Engl J Med. 2006; 355(2): 156-64. doi: 10.1056/NEJMoa052855.

13. Mari G., Deter R.L., Carpenter R.L., Rahman F., Zimmerman R., Moise K.J., Dorman K.F., Ludomirsky A., Gonzalez R., Gomez R., Oz U., Detti L., Copel J.A., Bahado-Singh R., Berry S., Martinez-Poyer J., Blackwell S.C. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. Collaborative Group for Doppler Assessment of the Blood Velocity in Anemic Fetuses. N Engl J Med. 2000; 342(1): 9 - 14. doi: 10.1056/NEJM200001063420102.

14. Михайлов А.В., Константинова Н.Н., Пигина Т.В. Внутриматочные переливания плоду как способ лечения отечной формы гемолитической болезни. Акушерство и гинекология. 1990; (7): 41-5.

15. Макогон А.В. Комплексная пренатальная диагностика и лечение гемолитической болезни плода: возможности и перспективы. Рос Вестник перинатологии и педиатрии. 2002; (6): 11-3.

16. Макогон А.А., Андрюшина И.В. Гемолитическая болезнь плода: мониторинг, лечение плода и родоразрешение. Вопросы гинекологии, акушерства и перинатологии. 2018; 17(3): 45 - 52.

17. Керимова Э.А., Путилова Н.В., Чистякова Г.Н., Пестряева Л.А., Устьянцева Н.Ю. Клинико-иммунологическое обоснование внутриутробных гемотрансфузий при гемолитической болезни плода по системе резус. Акушерство и гинекология. 2016; (12): 24-7.

18. UK Blood Transfusion Services. Guidelines for the Blood Transfusion Service. 8th ed. London: TSO; 2013.

19. Judelsohn R.G., Berger G.S., Wallace R.B., Tiller M.J. Rh-immune globulin in induced abortion: utilization in a high-risk population. Am J Obstet Gynecol. 1972; 114(8): 1031-4. doi: 10.1016/0002-9378(72)90864-2.

20. Delaney M., Matthews D.C. Hemolytic disease of the fetus and newborn: managing the mother, fetus, and newborn. Hematol Am Soc Hematol Educ Progr. 2015; 2015: 146-51. doi: 10.1182/asheducation-2015.1.146.

21. Harkness U.F., Spinnato J.A. Prevention and management of RhD isoimmunization. Clin Perinatol. 2004; 31(4): 721-42, vi. doi: 10.1016/j.clp.2004.06.005.

22. McBain R.D., Crowther C.A., Middleton P. Anti-D administration in pregnancy for preventing Rhesus alloimmunisation. Cochrane database Syst Rev. 2015; (9):CD000020. doi:10.1002/14651858.CD000020.pub3.

23. Chilcott J., Tappenden P., Lloyd Jones M., Wight J., Forman K., Wray J., Beverley C. The economics of routine antenatal anti-D prophylaxis for pregnant women who are rhesus negative. BJOG. 2004; 111(9): 903-7. doi: 10.1111/j.1471-0528.2004.00226.x.

24. Ravinet J., Carbonne B. [Economic analysis of the prevention of anti-D immunization]. J Gynecol Obstet Biol Reprod (Paris). 2006; 35(1 Suppl): 1S104-11.

25. Seeho S.K.M., Burton G., Leigh D., Marshall J.T., Persson J.W., Morris J.M. The role of preimplantation genetic diagnosis in the management of severe rhesus alloimmunization: first unaffected pregnancy: case report. Hum Reprod. 2005; 20(3): 697 - 701. doi: 10.1093/humrep/deh624.

26. National Institute for Clinical Excellence. Guidance on the use of routine antenatal anti-D prophylaxis for RhD-negative women. Technology Appraisal Guidance, N 41. London: National Institute for Clinical Excellence; 2002.

27. Brandenburg H., Jahoda M.G., Pijpers L., Wladimiroff J.W. Rhesus sensitization after midtrimester genetic amniocentesis. Am J Med Genet. 1989; 32(2): 225-6. doi: 10.1002/ajmg.1320320216.

28. American Academy of Pediatrics and the American College of Obstetricians and Gynecologists. Guidelines for perinatal care. 8th ed. Elk Grove Village, IL; Washington, DC; 2017.

29. American Academy of Pediatrics and the American College of Obstetricians and Gynecologists. Guidelines for perinatal care. 8th ed. Elk Grove Village, IL; Washington, DC; 2017.

30. Hill L.M., Platt L.D., Kellogg B. Rh sensitization after genetic amniocentesis. Obstet Gynecol. 1980; 56(4): 459-61.

31. Hensleigh P.A., Cann H. Rh sensitization after genetic amniocentesis. Obstet Gynecol. 1981; 58(1): 136.

32. Qureshi H., Massey E., Kirwan D., Davies T., Robson S., White J., Jones J., Allard S., British Society for Haematology. BCSH guideline for the use of anti-D immunoglobulin for the prevention of haemolytic disease of the fetus and newborn. Transfus Med. 2014; 24(1): 8 - 20. doi:10.1111/tme.12091.

33. Bennardello F., Coluzzi S., Curciarello G., Todros T., Villa S., Italian Society of Transfusion Medicine and Immunohaematology (SIMTI) and Italian Society of Gynaecology and Obstetrics (SIGO) working group. Recommendations for the prevention and treatment of haemolytic disease of the foetus and newborn. Blood Transfus. 2015; 13(1): 109-34. doi: 10.2450/2014.0119-14.

34. Bennardello F., Curciarello G. Survey on the prevention and incidence of haemolytic disease of the newborn in Italy. Blood Transfus. 2013; 11(4): 518-27. doi: 10.2450/2013.0179-12.

35. Shen R., Sandler S.G. Transfusion medicine illustrated. Miscounting even one lymphocyte in the Kleihauer-Betke (acid-elution) assay can result in overdosing Rh immune globulin. Transfusion. 2015; 55(9): 2069. doi: 10.1111/trf.13056.

36. Girard M., Marchand F., Uch R., Bretelle F. [Trauma and pregnancy: Is the Kleihauer-Betke test really useful?]. Gynecol Obstet Fertil Senol. 2017; 45(11): 584-9. doi: 10.1016/j.gofs.2017.08.009.

37. Spychalska J., Uhrynowska M., Pyl H., Klimczak-Jajor E., I., Peciakowska M., Gutowska R., Gawlak M., S., S., Szczecina R., M., Brojer E. [Standardization of the quantitative flow cytometric test with anti-D antibodies for fetomaternal hemorrhage in RhD negative women]. Ginekol Pol. 2015; 86(7): 486-93. doi: 10.17772/gp/57854.

38. Lebrun B., Jacquemyn Y. Usefulness of maternal fetal red blood cell count in rhesus-positive pregnant women. Horm Mol Biol Clin Investig. 2018; 35(3). doi: 10.1515/hmbci-2018-0028.

39. Samson D., Mollison P.L. Effect on primary Rh immunization of delayed administration of anti-Rh. Immunology. 1975; 28(2): 349-57.

40. Deka D., Dadhwal V., Sharma A.K., Shende U., Agarwal S., Agarwal R., Vanamail P. Perinatal survival and procedure-related complications after intrauterine transfusion for red cell alloimmunization. Arch Gynecol Obstet. 2016; 293(5): 967-73. doi: 10.1007/s00404-015-3915-7.

41. Lindenburg I.T.M., van Kamp I.L., Oepkes D. Intrauterine blood transfusion: current indications and associated risks. Fetal Diagn Ther. 2014; 36(4): 263-71. doi: 10.1159/000362812.

42. I., S., Z., O., R., D., N. Middle cerebral artery Doppler in prediction degree of fetal anemia and the best timing for the second intrauterine intravascular transfusion in red cell alloimmune disease. Clin Exp Obstet Gynecol. 2015; 42(6): 792-6.

43. N., R., A., J. [Role of middle cerebral artery Doppler in the management of Rhesus alloimmunization cases]. Ginecol Obstet Mex. 2010; 78(8): 410-7.